Unicycive Therapeutics Inc
Change company Symbol lookup
Select an option...
UNCY Unicycive Therapeutics Inc
ATRC AtriCure Inc
CTRA Coterra Energy Inc
CINF Cincinnati Financial Corp
ATOM Atomera Inc
IEAWW Infrastructure and Energy Alternatives 27 March 2023 *W EXP 03/27/2023
SLAC Social Leverage Acquisition Corp I
CNNXF Cannamerica Brands Corp
BA Boeing Co
COP Conocophillips

Health Care : Biotechnology |
Company profile

Unicycive Therapeutics, Inc. is a biotechnology company dedicated to developing treatments for certain medical conditions. The Company is focused on identifying medical conditions within and outside of kidney disease. Its development programs are focused on the development of two therapies: Renazorb, for treatment of hyperphosphatemia in patients with chronic kidney disease (CKD), and UNI 494, for treatment of acute kidney injury (AKI). Renazorb was initially developed by, and licensed from, Spectrum Pharmaceuticals. UNI 494 was initially developed by, and licensed from Sphaera Pharmaceuticals, respectively. CKD is the gradual loss of kidney function, which leads to electrolyte imbalances, fluid build-up, anemia, bone disease, and heart disease. Hyperphosphatemia is an electrolyte disorder in which untreated elevated phosphate levels in the blood lead to cardiovascular complications and vascular calcification.

Day's Change
0.0028 (0.34%)
B/A Size
Day's High
Day's Low
(Above Average)

Today's volume of 2,030 shares is on pace to be greater than UNCY's 10-day average volume of 18,719 shares.

  • Prev Close
  • Today's Open
  • Day's Range
  • Avg Vol (10-day)
  • Last (time)
    9:56a ET 07/01/22
  • Last (size)
  • 52-Wk Range
    0.624 - 8.73
  • (07/13/21 - 05/09/22)
  • 96.4%
  • Market Cap
  • Shares Outstanding
  • -0.86
  • --
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • --
  • 19.44
  • (% of float 06/15/22)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.